

Pharmacogenomics Testing



Medicaid Medical Coverage Policy

Original Effective Date: 04/01/2025

Effective Date: 07/22/2026

Review Date: 04/07/2026

Policy Number: HUM-SC-2240-003

Line of Business: Medicaid

State(s): SC

Table of Contents

[Description](#)

[Coding Information](#)

[Change Summary](#)

[Coverage Determination](#)

[References](#)

Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Description

Pharmacogenomics testing is a type of genetic laboratory testing that analyzes inherited variations (mutations) in an individual's genes to predict how that individual may metabolize, respond to or experience adverse reactions from specific medications. Results are used to guide medication selection and dosing with the goal of improving therapeutic outcomes and reducing the risk of adverse drug reactions.

Molecular pathology testing is a laboratory technique that detects molecular abnormalities, such as variants, by analyzing DNA, RNA and proteins within cells and tissues. The tests are used to diagnose, monitor and guide treatment for diseases like cancer and genetic disorders.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines that classify drug-gene interactions according to the strength of supporting evidence thereby assisting clinicians in making informed prescribing decisions. Testing is guided by CPIC recommendations to identify relevant drug-gene interactions and optimize care.

Coverage Determination

ChemoFx Assay

Humana members may be eligible under the Plan for **ChemoFx Assay (81535/81536)** to determine how cancer cells may respond to chemotherapeutic agents for an individual diagnosed with gynecologic cancer

(eg, cervical, endometrial, fallopian tube, gynecologic sarcoma, ovarian, primary peritoneal) for the following indications¹:

- Diagnosed with a rare cancer with no established treatment guidelines; **OR**
- During initial biopsy or surgery; **OR**
- Recurrent cancer; **OR**
- Treatment-refractory; **OR**
- Unable to tolerate recommended treatment

Molecular Pathology Testing

Humana members may be eligible under the Plan for **molecular pathology testing (81479) for pharmacogenomics analysis** when the individual is being treated with or considered for treatment with a medication with a known gene-drug interaction per Food and Drug Administration (FDA) labeling or [Clinical Pharmacogenetics Implementation Consortium \(CPIC\)](#) guideline level A or B.

For members under age 21, requests are reviewed for medical necessity in accordance with Early and Periodic Screening, Diagnostic and Treatment (EPSDT) requirements.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81479	Unlisted molecular pathology procedure	
81535	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination	
81536	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)	
CPT® Category III Code(s)	Description	Comments
No code(s) identified		

HCP Code(s)	Description	Comments
No code(s) identified		

References

1. Hayes, Inc. Molecular Test Assessment. ChemoFx Assay (Helomics). <https://evidence.hayesinc.com>. Published December 2, 2020. Updated December 11, 2023.

Change Summary

04/01/2025 New Policy.

05/06/2025 Update, Coverage Change. Provider Claims Codes Update.

11/04/2025 Update, Coverage Change. Updated Coding Information.

04/07/2026 Annual Review, Coverage Change. Updated Coding Information.